secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001104659-24-058747
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q1 net income $36.5M ($0.58 basic EPS); product sales up 66% YoY to $19.1M; GSK royalties $61.9M
--------------------------------------------------------------------------------

- Net income $36.5M ($0.58 basic EPS) vs $34.9M ($0.51) in Q1 2023.
- Net product sales $19.1M, +66% YoY, driven by XACDURO launch and GIAPREZA growth.
- GSK royalty revenue $61.9M, up from $60.3M in Q1 2023.
- Repurchased 0.6M shares for $9.7M in Q1 2024; completed $5.3M buyback post-quarter.
- Positive Phase 3 zoliflodacin results for uncomplicated gonorrhea; NDA submission expected early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465924058747/0001104659-24-058747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465924058747/tm2413603d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-058747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer